MedTrace Logo

Chemotherapy, Host Response and Molecular Dynamics in Periampullary Cancer

NCT03724994 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 201

Last updated 2025-08-29

No results posted yet for this study

Summary

The CHAMP (Chemotherapy, Host response And Molecular dynamics in Periampullary cancer) study is a prospective, single-arm observational study that started Sept 1 2018. Patients diagnosed with pancreatic or other periampullary adenocarcinoma undergoing adjuvant och palliative chemotherapy are invited to participate. The study will examine the tumors' molecular dynamics and how this may change over time and with treatment. Primary endpoint will be overall survival, secondary endpoints will be disease specific survival, time to progression, and quality of life. We estimate that 90 patients will be included in the study per year.

Conditions

Interventions

DRUG

Gemcitabine

Adjuvant or palliative chemotherapy according to national guidelines

Sponsors & Collaborators

  • Lund University

    lead OTHER

Principal Investigators

  • Karin Jirström, Professor · Lund University

  • Karin Leandersson, Professor · Lund University

  • Margareta Heby, MD · Lund University

  • Sofie Olsson Hau, MD · Lund University

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-10-30
Primary Completion
2024-12-31
Completion
2024-12-31

Countries

  • Sweden

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03724994 on ClinicalTrials.gov